Lakefront Biotherapeutics NV current report, Q4 FY2025

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV, a foreign private issuer, for the month of October 2025. The filing, dated October 24, 2025, incorporates by reference a press release issued on October 23, 2025 (Exhibit 99.1). The registrant's principal executive office is located in Mechelen, Belgium. Note: While the request metadata mentions "Lakefront Biotherapeutics NV," the filing text explicitly identifies the registrant as Galapagos NV.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely as a vehicle to incorporate a press release by reference and does not contain a financial statement or quantitative data within the provided text.

Material Changes

The filing text does not disclose specific material changes versus prior periods. It references a press release (Exhibit 99.1) for details, but the content of that press release is not included in the provided input text.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or descriptions of unusual items. These details are presumed to be contained within the referenced Exhibit 99.1 press release, which is not part of the provided text.

Investor Verification Checklist

  • Verify the content of the press release dated October 23, 2025 (Exhibit 99.1), as the filing itself contains no operational or financial details.
  • Confirm the identity of the registrant as Galapagos NV, noting the discrepancy with the "Lakefront Biotherapeutics NV" name in the request metadata.
  • Review the incorporated Registration Statements on Form S-8 listed in the filing for historical context on equity plans.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.